Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

Cinfa Biotech S.L.. (5/17/17). "Press Release: Cinfa Biotech Announces Positive Top-line Data from Second Clinical Study with Pegfilgrastim Biosimilar Candidate B12019". Pamplona.

Region Region Germany
Organisations Organisation Cinfa Biotech GmbH
  Group Infarco (Group)
  Organisation 2 EMA (European Medicines Agency)
  Group EU (govt)
Products Product B12019 (pegfilgrastim biosimilar, Cinfa Biotech)
  Product 2 clinical research
Person Person Jankowsky, Rüdiger (Infarco 201510– Managing Director at Cinfa Biotech GmbH)
     


Cinfa Biotech S.L., the biosimilars company of Cinfa Group, today announced positive top-line data from the second clinical trial with its lead development candidate B12019, a biosimilar version of Neulasta® (pegfilgrastim) to treat chemotherapy-induced neutropenia. The trial demonstrated comparability of B12019 and its reference product Neulasta with regards to pharmacodynamics (PD) and immunogenicity. All primary and secondary study endpoints were met.

The multiple-dose, randomised, double-blind, three-period cross-over study enrolled 96 healthy volunteers in Germany. The study design was based on scientific advice from the European Medicines Agency (EMA) and was tailored to the specific properties of pegfilgrastim. The study met its primary endpoints: area under the effect curve (AUEC0-last) for PD and anti-drug antibody rate (ADA) for immunogenicity, confirming comparability to Neulasta. Likewise, all secondary endpoints were achieved. The safety of B12019 was also comparable to Neulasta. Further data from the trial will be presented at upcoming scientific conferences.

Dr Ruediger Jankowsky, Managing Director of Cinfa Biotech GmbH, commented:

”The positive results of our second study confirm the biosimilarity of B12019 and Neulasta that we demonstrated in the first trial. Both studies, together with the analytical and functional comparability data, support the high quality of our product candidate. Based on the now available comprehensive data package for B12019, we are preparing to submit for EU approval in the second half of 2017. I am proud of the team for having completed such an efficient clinical development program on time.”

Pegfilgrastim is indicated for the treatment of chemotherapy-induced neutropenia. The pegylated granulocyte colony-stimulating factor (G-CSF) receptor agonist is used to stimulate bone marrow to produce more neutrophils to decrease the incidence of infection in patients undergoing chemotherapy.


About Cinfa Biotech

Cinfa Biotech is headquartered in Pamplona, Spain, with offices in Munich, Germany. Founded in 2013 and supported by its parent company Cinfa Group, the Company is creating a pipeline of biosimilar drugs for a range of indications to address the growing need for affordable therapies based on proven science, quality, safety and efficacy. A complete team of experts with decades of in-depth experience is conducting product development, clinical studies, manufacturing and quality control, according to the highest European standards. Cinfa Biotech’s first product candidate in clinical development is B12019, a biosimilar version of Neulasta® (pegfilgrastim). The commercialisation models will be customised to the needs of partners and markets.

With 50 years’ experience, Cinfa Group today employs over 1,400 people and reinvests an average of 90% of its annual profits in its portfolio companies, thereby driving their development and innovation. Cinfa Group’s first subsidiary, Laboratorios Cinfa, has become a recognised leader in the Spanish pharmaceutical market. As part of the internationalization strategy, the company also serves in currently over 50 countries and is further expanding.

For more information, please visit: http://www.cinfabiotech.com


For press enquiries:

MC Services AG
Julia von Hummel, Shaun Brown
Phone: +49 89 210 228-0
Email: cinfabiotech[at]mc-services.eu


Neulasta® is a registered trademark of Amgen Inc.

   
Record changed: 2017-06-07

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Infarco (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px